The Latest Urologic Oncology Journal Articles

Keep up to date with the latest in urologic oncology. Check out the latest diabetes articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily

• Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.14th February 2021
  Little is known about health-related quality of life (HRQOL) following treatment for bladder cancer (BC).To determine this, we undertook a cross-sectional survey covering 10% of the English population.Participants 1-10 yr from diagnosis were identified through national cancer registration data.A postal survey was administered containing generic HRQOL and BC-specific outcome measures. Findings were compared with those of […]
• Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.13th February 2021
  Whether AR-V7 expression can predict the response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) remains to be explored.To evaluate the predictive value of AR-V7 expression in the prognosis of mHSPC patients receiving ADT.In this multicenter prospective cohort study, 310 mHSPC patients commencing ADT were enrolled. Standard immunohistochemical staining […]
• A Systematic Review and Scoping Analysis of Smoking Cessation after a Urologic Cancer Diagnosis.12th February 2021
  Smoking cessation after a urologic cancer diagnosis significantly benefits patients. It is not well known how often patients quit after diagnosis or how urologists intervene to support patients’ smoking cessation efforts.To examine rates of smoking cessation after diagnosis among patients with urologic cancers and to assess how often patients are given advice and support to […]
• Micro-Ultrasound-guided Versus Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.12th February 2021
  Micro-ultrasound is a novel, high-resolution, ultrasound technology, aiming to improve prostate imaging and, consequently, the diagnostic accuracy of ultrasound-guided prostate biopsy (PB). Micro-ultrasound-guided PB may present comparable detection rates to, the standard of care, multiparametric magnetic resonance imaging (mpMRI)-targeted PB for the diagnosis of clinically significant prostate cancer (PCa). We aimed to compare the detection […]
• The Clinical Significance of Bone Mineral Density Changes Following Long Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.12th February 2021
  Long-term androgen deprivation therapy (LT-ADT) has been associated with decreased bone mineral density (BMD) in men with prostate cancer (PCa). Some evidence suggests that there is no impact on fracture risk despite this BMD loss. Our study aimed to quantify changes in BMD in men with high risk PCa on LT-ADT and calcium and vitamin […]
• Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass.9th February 2021
  With the addition of active surveillance and thermal ablation (TA) to the urologist’s established repertoire of partial (PN) and radical nephrectomy (RN) as first-line management options for localized renal cell carcinoma (RCC), appropriate treatment decision-making has become increasingly nuanced.To critically review the treatment options for localized, nonrecurrent RCC; to highlight the patient, renal function, tumor, […]
• Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer.10th January 2021
  Hyperinsulinemia and inflammation are inter-related pathways that link diet with the risk of several chronic diseases. Evidence suggests that these pathways may also increase prostate cancer risk.To determine whether hyperinsulinemic diet and inflammatory diet are associated with prostate cancer incidence and mortality.We prospectively followed 41 209 men in the Health Professionals Follow-up Study (1986-2014). Scores […]
• Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.10th January 2021
  Genomic stratification can impact prostate cancer (PC) care through diagnostic, prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and spatial genomic heterogeneity of PC together with the challenges of acquiring metastatic tissue biopsies hinder implementation of tissue-based molecular profiling in routine clinical practice. Blood-based liquid biopsies are an attractive, minimally invasive alternative.To […]
• European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.9th January 2021
  The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the […]
• The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.9th January 2021
  Emerging data suggest that metastasis is a spectrum of disease burden rather than a binary state, and local therapies, such as radiation, might improve outcomes in oligometastasis. However, current definitions of oligometastasis are solely numerical.To characterize the somatic mutational landscape across the disease spectrum of metastatic castration-sensitive prostate cancer (mCSPC) to elucidate a biological definition […]
• Value-Based Healthcare in Urology: A Collaborative Review.8th January 2021
  In response to growing concerns over rising costs and major variation in quality, improving value for patients has been proposed as a fundamentally new strategy for how healthcare should be delivered, measured, and remunerated.To systematically review the literature regarding the implementation and impact of value-based healthcare in urology.A systematic review was performed to identify studies […]
• The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.4th January 2021
  Studies have conflicting results regarding the association between statin use and biochemical recurrence for prostate cancer (PCa). A limited number of studies examining statins in advanced stages report positive results, with a few specifically examining statins and androgen deprivation therapy (ADT).To perform a post hoc secondary analysis of a randomised controlled trial (RCT) of men […]
• Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.28th December 2020
  Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A […]
• Robot-assisted Radical Prostatectomy Using Single-port Perineal Approach: Technique and Single-surgeon Matched-paired Comparative Outcomes.28th December 2020
  Radical perineal prostatectomy (RPP) has been revived with the advent of single-port (SP) robotic surgery. However, its interest and precise role need to be evaluated and better defined.To describe in detail the technique of SP-RPP and compare initial perioperative outcomes with those of multiport robot-assisted transperitoneal radical prostatectomy (MP-RARP).From October 2018 to June 2020, perioperative […]
• Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.28th December 2020
  Enzalutamide plus ADT has previously been shown to improve clinical outcomes in men with metastatic hormone sensitive prostate cancer (ARCHES; NCT02677896). Here, we assessed if and how the pattern of metastatic spread impacts efficacy of enzalutamide plus ADT in men enrolled in ARCHES.Men with metastatic hormone sensitive prostate cancer were randomized 1:1 to enzalutamide (160 […]
• Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients.28th December 2020
  Cigarette smoking is a risk factor for developing non-muscle invasive bladder cancer (NMIBC) and continued smoking exposure after diagnosis may increase the likelihood of adverse clinical outcomes. Here we compare self-reported vs. biochemically-verified nicotine exposure to determine the accuracy of self-report among recently diagnosed NMIBC patients.This cross-sectional analysis consisted of 517 NMIBC patients who contributed […]
• Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.28th December 2020
  Microhematuria is a prevalent condition and the American Urological Association (AUA) has developed a new risk-stratified approach for the evaluation of patients with microhematuria. Our objective was to provide the first evaluation of this important guideline.This multi-national cohort study combines contemporary patients from five clinical trials and two prospective registries who underwent urologic evaluation for […]
• Heterogeneity in Genomic Risk Assessment From Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of MRI Targeted Biopsy.28th December 2020
  Genomic prognostic signatures are used on prostate biopsy tissue for cancer risk assessment, but tumor heterogeneity and multi-focality may be an issue. We evaluated the variability in genomic risk assessment from different biopsy cores within the prostate using three prognostic signatures (Decipher, CCP, GPS).Men in this study came from two prospective prostate cancer trials of […]
• MRI-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer.28th December 2020
  Active surveillance for patients with low and intermediate risk prostate cancers is becoming a more utilized option in recent years. However, the use of MRI and MRI-targeted biopsy for monitoring grade progression has been poorly studied in this population. We aim to show the utility of MRI-targeted biopsy over systematic biopsy in an active surveillance […]
• Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry.28th December 2020
  A paradigm shift in management of small renal masses has increased utilization of active surveillance. However, questions remain regarding safety and durability in younger patients.Patients aged 60 or younger at diagnosis were identified from the Delayed Intervention and Surveillance for Small Renal Masses registry. The active surveillance, primary intervention, and delayed intervention groups were evaluated […]
• Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.28th December 2020
  Nonmuscle-invasive bladder cancer is treated by resection within the bladder and bladder instilment with BCG or chemotherapy. For BCG-refractory disease, systemic anti-PD-1 immune checkpoint inhibition is a treatment. Our aim is to test whether intravesical instilment with anti-PD-1 inhibitor treats localized bladder cancer as effectively as systemic administration.We investigated an orthotopic mouse model of urothelial […]
• Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.22nd December 2020
  Identify new information evaluating clinically localized prostate cancer (CLPC) therapies.Bibliographic databases (2013-January 2020); ClinicalTrials.gov; and systematic reviews were searched for controlled studies of CLPC treatments; duration ≥5 years for mortality and metastases and ≥1 year for harms.We identified 67 eligible references. Among clinically, rather than prostate-specific antigen (PSA) detected CLPC, Watchful Waiting (WW) may increase […]
• Other- and All-Cause Mortality Among Men Diagnosed with Prostate Cancer in the PLCO Trial.22nd December 2020
  Men with prostate cancer (PCa) have high cause-specific survival, and most deaths are of other causes. This study aimed to investigate other- and all-cause mortality in a large cancer screening cohort.From the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial cohort, we selected men diagnosed with PCa from 1994-2014. We examined other- and all-cause […]
• Measuring Bladder Health: Development and Cognitive Evaluation of Items for a Novel Bladder Health Instrument.22nd December 2020
  To describe the item development and cognitive evaluation process used in creating the Prevention of Lower Urinary Tract Symptoms Bladder Health Instrument (PLUS-BHI).Questions assessing bladder health were developed using reviews of published items, expert opinion, and focus groups’ transcript review. Candidate items were tested through cognitive interviews with community-dwelling women and an online panel survey. […]
• Patterns of Current Cigarette Smoking, Quit Attempts, and Cessation Counseling Among Survivors of Smoking Related and Non-smoking Related Urologic Malignancies: A Nationally Representative Cross-Sectional Analysis.21st December 2020
  Cigarette smoking is the leading modifiable risk factor for several genitourinary (GU) malignancies. Although smoking cessation after GU cancer diagnosis is a critical component of survivorship, factors related to continued smoking are understudied.A cross-sectional analysis was conducted using data from the NHIS (2014-2018). Our primary study outcome was the prevalence and correlates of cigarette smoking […]
• Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.20th December 2020
  Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) into routine care, it is important to assess if the benefits justify the differences in resource use.To determine the cost-effectiveness of PSMA-PET/CT when compared with conventional imaging.A cost-effectiveness analysis was developed using data from the proPSMA study. proPSMA included patients with high-risk prostate cancer […]
• Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated HRR Gene Alterations.17th December 2020
  To characterize the global epidemiology of metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC). Additionally, to assess the prevalence of homologous recombination repair gene alterations (HRRm) and their prognostic impact in advanced disease setting.A systematic literature review of real-world evidence (RWE) published 01/2009-05/2019 was conducted to assess global […]
• Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.14th December 2020
  To determine early efficacy of bipolar radiofrequency ablation with a coil design (bRFA) for focal ablation of clinically significant localised prostate cancer (sPCa)visible at mpMRI.A prospective IDEAL phase 2 development study (NCT02294903) recruited treatment naive patients with a single focus of localised sPCa (Gleason 7 or 4 mm or more of Gleason 6) concordant with […]
• A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).14th December 2020
  Management of locally recurrent prostate cancer after definitive radiotherapy remains controversial due to the perceived high rates of severe genitourinary (GU) and gastrointestinal (GI) toxicity associated with any local salvage modality.To quantitatively compare the efficacy and toxicity of salvage radical prostatectomy (RP), high-intensity focused ultrasound (HIFU), cryotherapy, stereotactic body radiotherapy (SBRT), low-dose-rate (LDR) brachytherapy, and […]
• Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.11th December 2020
  Grade group 4 and 5 (GG-45) prostate cancer (PCa) patients are at the highest risk of lethal outcomes, yet lack genomic risk stratification for prognosis and treatment selection. Here, we assess whether transcriptomic interactions between tumor immune content score (ICS) and the Decipher genomic classifier can identify most lethal subsets of GG-45 PCa. We utilized […]
• Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.9th December 2020
  The role of extended pelvic lymph node dissection (EPLND) in the surgical management of prostate cancer (PCa) patients remains controversial, mainly because of a lack of randomized controlled trials (RCTs).To determine whether EPLND has better oncological outcomes than limited PLND (LPLND.This was a prospective, single-center phase 3 trial in patients with intermediate- or high-risk clinically […]
• A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.9th December 2020
  Molecular biomarkers aim to address the established limitations of clinicopathologic factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to whether sufficient evidence supports adoption of these biomarkers for clinical use.To perform a systematic review of the available evidence supporting the clinical utility of the Decipher genomic classifier (GC).The review was […]
• Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.9th December 2020
  BC2001 demonstrated improved local control with the addition of chemotherapy to radiotherapy in 360 patients with muscle-invasive bladder cancer.To establish whether such benefit remained in BC2001 patients who received prior neoadjuvant chemotherapy.A total of 117 patients (33%) received neoadjuvant chemotherapy and were randomised to radiotherapy with (48%) or without (52%) concomitant chemotherapy. Patients were recruited […]
• Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.9th December 2020
  Beta-emitting Lu-177-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (mCRPC), but its antitumor effect can decrease over time.To report the safety and activity of alpha-emitting Ac-225-PSMA-617 RLT in mCRPC that has progressed after Lu-177-PSMA.Twenty-six patients were treated under a compassionate use protocol. The eligibility criteria included […]
• Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis.7th December 2020
  Ureteral stenting in patients with bladder cancer may become necessary in order to protect the ureteral orifice during transurethral resection of the tumor or for relief of upper urinary tract (UUT) obstruction. However, it is believed to increase metachronous upper tract urothelial carcinoma (UTUC) risk.We performed a systematic review and meta-analysis of studies comparing ureteral […]
• Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.6th December 2020
  Ductal prostate adenocarcinoma (DAC) is a rare, aggressive, histologic variant of prostate cancer that is treated with conventional therapies, similar to high-risk prostate adenocarcinoma (PAC).To assess the outcomes of men undergoing definitive therapy for DAC or high-risk PAC and to explore the effects of androgen deprivation therapy (ADT) in improving the outcomes of DAC.A single-center […]
• Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.1st December 2020
  Single nucleotide polymorphism-based genetic risk score (GRS) has been developed and validated for prostate cancer (PCa) risk assessment. As GRS is population standardized, its value can be interpreted as a relative risk to the general population.To compare the performance of GRS with two guideline-recommended inherited risk measures, family history (FH) and rare pathogenic mutations (RPMs), […]
• Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals.30th November 2020
  One in six gay and bisexual men will be diagnosed with prostate cancer in their lifetime. Lesbian, gay, bisexual, and transgender (LGBT) populations are under-represented in cancer research, and guidelines on prostate-specific antigen (PSA) screening are limited. We performed a cross-sectional study to assess patterns of PSA screening and decision-making in this cohort. The Behavioral […]
• Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer.30th November 2020
  Contemporary treatment modalities for localized prostate cancer provide comparable overall and cancer-specific survival. However, the degree of financial burden imposed by treatment, the factors contributing to that burden, and how different treatments compare with regard to financial toxicity remain poorly understood.The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study enrolled men with localized prostate […]
• Race, Decisional Regret and Prostate Cancer Beliefs: Identifying Targets to Reduce Racial Disparities in Prostate Cancer.23rd November 2020
  African American men are more likely to be diagnosed with, die of and experience decisional regret about their prostate cancer than nonAfrican American men. Although clinical discrepancies may be attributed to genetic risk and/or access to care, explanations for racial discrepancies in decisional regret remain largely speculative. We aim to identify sources of prostate cancer […]
• Selecting Patients with Favourable-Risk, GG2 Prostate Cancer for Active Surveillance: Does MRI Have a Role?20th November 2020
  The National Comprehensive Cancer Network (NCCN) recommends that selected men with GG2 (Grade Group 2) prostate cancer be considered for active surveillance (AS). However, selecting which patients with GG2 disease can be safely managed with AS remains controversial.The aim of this study was to evaluate the association of multiparametric MRI (mpMRI) with adverse pathology in […]
• A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy.18th November 2020
  The DROP-IN gamma probe was introduced to overcome the restricted manoeuvrability of traditional laparoscopic gamma probes. Through enhanced manoeuvrability and surgical autonomy, the DROP-IN promotes the implementation of radioguided surgery in the robotic setting.To confirm the utility and safety profile of the DROP-IN gamma probe and to perform a comparison with the traditional laparoscopic gamma […]
• Initial Experience with Intracorporeal Laparoscopic Radical Cystectomy and Detaenial Sigmoid Neobladder Reconstruction.18th November 2020
  Intracorporeal urinary diversion is considered to be effective in improving intestinal function recovery and reducing the occurrence of early complications after radical cystectomy. Almost all neobladders constructed via intracorporeal laparoscopy have used the ileum.To present our intracorporeal detaenial sigmoid neobladder technique that replicates open surgery principles and to present oncological and functional outcomes and complication […]
• Can 68Ga-PSMA-11 PET/CT Predict Pathologic Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy: A Pilot Study.18th November 2020
  To explore the role of 68Ga-PSMA-11 PET/CT as a predictor of pathologic response to neoadjuvant androgen deprivation therapy (ADT) combined with abiraterone for high-risk prostate cancer (PCa).Forty-five patients with localized high-risk PCa who had serial 68Ga-PSMA-11 PET/CT scans before and after 6-month of ADT plus abiraterone neoadjuvant treatment, followed by radical prostatectomy, were included in […]
• PSMA PET/CT in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.18th November 2020
  To assess predictors for the short-term oncological outcome of patients who underwent salvage radiation therapy (SRT) for biochemical recurrence (BCR) after robot-assisted laparoscopic radical prostatectomy (RARP), without evidence of metastases on prostate-specific membrane antigen (PSMA) PET/CT.A total of 194 patients with BCR after RARP who underwent a PSMA PET/CT prior to SRT were retrospectively analyzed. […]
• A Comparison of Prostate Cancer Detection Between Visual-Estimation (Cognitive Registration) and Image-Fusion (Software Registration) Targeted Transperineal Prostate Biopsy.18th November 2020
  To compare clinically significant prostate cancer (csPCa) detection by visual-estimation and image-fusion targeted transperineal prostate biopsy.This multi-centre study included patients with multiparametric MRI (mpMRI) lesions undergoing visual-estimation or image-fusion targeted transperineal biopsy (April/2017-March/2020). Propensity score matching was performed using demographics (age and ethnicity), clinical features (PSA, prostate volume, PSA-density and digital rectal examination), mpMRI variables […]
• Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pre-treatment Prostate MRI Findings.18th November 2020
  To investigate whether T2-weighted magnetic resonance imaging (MRI) findings could improve upon established prognostic indicators of metastatic disease and cancer-specific survival.For a cohort of 3,406 consecutive men who underwent prostate MRI before definitive prostatectomy (n=2,160) or radiotherapy (n=1,246) between 2001 and 2006, T2-weighted MRI exams were retrospectively interpreted and categorized as (I) No focal suspicious […]
• The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?17th November 2020
  Men with low risk prostate cancer on active surveillance undergo multiple biopsies over time. The long-term clinical significance of consecutively negative biopsies is not known.Men with low risk prostate cancer prospectively enrolled in an active surveillance database with at least 4 biopsies were included in the study. Exposure variables were 0, 1 or 2 consecutively […]
• T1-Substaging of Non-muscle Invasive Bladder Cancer is Associated with BCG-Failure and Improves Patient Stratification at Diagnosis.16th November 2020
  Currently, markers are lacking that can identify high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients who fail BCG-treatment. Therefore, we evaluated the prognostic value of T1-substaging in primary HR-NMIBC.Patients with primary HR-NMIBC who received ≥5 BCG-induction instillations were included. All tumors were centrally reviewed, which included T1-substaging (micro [T1m] vs extensive [T1e] lamina propria invasion). T1 […]
• Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.13th November 2020
  Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond.To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset.We studied advanced PC biopsies using validated immunohistochemical (IHC) and next-generation sequencing (NGS) assays. In vitro cell […]
• Surgical Management of Retrocrural Disease in Germ Cell Tumors: Outcomes and Evolution of Practice.12th November 2020
  Residual retrocrural disease in testis cancer following chemotherapy is a surgical challenge. We sought to assess the outcomes and evolution with surgical management of residual retrocrural disease.We identified 2,788 testicular cancer patients from 1990-2010 who underwent retroperitoneal surgery for metastatic testicular cancer at our institution. Patients who also underwent post-chemotherapy staged or concurrent retrocrural dissections […]
• Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.11th November 2020
  Although grading systems have been proposed for chromophobe renal cell carcinoma (ChRCC), including a three-tiered system by Paner et al (Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 2010;34:1233-40), none have gained clinical […]
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.11th November 2020
  To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).The panel performed a literature review of […]
• The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.7th November 2020
  We assessd the long-term outcomes from a large prospective cohort of men diagnosed with prostate cancer managed with active surveillance and determined the clinical prognostic factors that may predict the risk of metastases.We retrospectively reviewed data of men enrolled on active surveillance at our institution between 1990 and 2018 with low or intermediate risk disease […]
• Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.6th November 2020
  Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown clinical benefit in a subset of patients, but the mechanistic basis and biomarkers remain elusive.To identify mechanisms and response indicators for the antitumor efficacy of taxane-platinum combinations […]
• Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.5th November 2020
  Distinguishing indolent from aggressive prostate cancer remains a key challenge for decision making regarding prostate cancer management. A growing number of biomarkers are now available to help address this need, but these have rarely been examined together in the same patients to determine their potentially additive value.To determine whether two previously validated plasma markers (transforming […]
• Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance.3rd November 2020
  There is concern that African American men with low-risk prostate cancer may harbor more aggressive disease than non-Hispanic White men. Therefore, it is unclear whether active surveillance is a safe option for African American men.To compare clinical outcomes of African American and non-Hispanic White men with low-risk prostate cancer managed with active surveillance.Retrospective cohort study […]
• Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence.29th October 2020
  Focal instead of whole gland ablation for prostate cancer has been proposed to decrease treatment morbidity. We sought to determine differences in erectile function and urinary continence after focal and whole gland ablation for prostate cancer.From 2009 to 2018, 346 patients underwent high intensity focused ultrasound or cryotherapy for prostate cancer. Urinary continence was defined […]
• Performance of Prostate Health Index (PHI) in Biopsy-Naïve Black Men.26th October 2020
  Prostate Health Index (PHI) is validated for prostate cancer (PCa) detection but has not been well validated for Gleason grade group (GG) 2-5 PCa detection in Black men. We hypothesize that PHI has greater accuracy than PSA for detection of GG2-5 PCa. We estimated probability of overall and GG2-5 PCa across previously established PHI ranges […]
• An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment.23rd October 2020
  In the USA, it is unknown whether metastatic prostate cancer incidence has continued to increase and whether racial differences have persisted.Combining multiple imputation with age and delay adjustment, we provide an up-to-date, comprehensive assessment of US prostate cancer incidence trends by stage and race.From Surveillance Epidemiology and End Results (SEER)-18, 774 240 prostate cancer cases […]